Clarke JTR - Search Results

1

Punctate calcifications in lysosomal storage disorders.

Schwartz IVD, Artigalás O, Ries M, Clarke JTR, Giugliani R, Beck M. Schwartz IVD, et al. Among authors: clarke jtr. Clin Dysmorphol. 2009 Jul;18(3):172-177. doi: 10.1097/MCD.0b013e32832a9ed5. Clin Dysmorphol. 2009. PMID: 19339876 No abstract available.

2

Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).

Clarke JT, Giugliani R, Sunder-Plassmann G, Elliott PM, Pintos-Morell G, Hernberg-Ståhl E, Malmenäs M, Beck M; FOS Investigators. Clarke JT, et al. Value Health. 2011 Sep-Oct;14(6):862-6. doi: 10.1016/j.jval.2011.05.002. Epub 2011 Jun 23. Value Health. 2011. PMID: 21914507 Free article.

3

The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.

Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, Giugliani R, Mahuran D, Clarke JT. Maegawa GH, et al. Pediatrics. 2006 Nov;118(5):e1550-62. doi: 10.1542/peds.2006-0588. Epub 2006 Oct 2. Pediatrics. 2006. PMID: 17015493 Free PMC article. Review.

4

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R. Ries M, et al. J Clin Pharmacol. 2007 Oct;47(10):1222-30. doi: 10.1177/0091270007305299. Epub 2007 Aug 13. J Clin Pharmacol. 2007. PMID: 17698592 Clinical Trial.

5

A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.

Giugliani R, Rojas VM, Martins AM, Valadares ER, Clarke JT, Góes JE, Kakkis ED, Worden MA, Sidman M, Cox GF. Giugliani R, et al. Mol Genet Metab. 2009 Jan;96(1):13-9. doi: 10.1016/j.ymgme.2008.10.009. Epub 2008 Nov 26. Mol Genet Metab. 2009. PMID: 19038563 Clinical Trial.

6

Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Rohrbach M, Clarke JT. Rohrbach M, et al. Drugs. 2007;67(18):2697-716. doi: 10.2165/00003495-200767180-00005. Drugs. 2007. PMID: 18062719 Review.

7

Neuroradiology of lysosomal disorders.

Blaser SI, Clarke JT, Becker LE. Blaser SI, et al. Neuroimaging Clin N Am. 1994 May;4(2):283-98. Neuroimaging Clin N Am. 1994. PMID: 8081629 Review.

8

Agalsidase alfa and kidney dysfunction in Fabry disease.

West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. West M, et al. J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8. J Am Soc Nephrol. 2009. PMID: 19357250 Free PMC article.

9

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT; Fabry Outcome Survey investigators. Mehta A, et al. Lancet. 2009 Dec 12;374(9706):1986-96. doi: 10.1016/S0140-6736(09)61493-8. Lancet. 2009. PMID: 19959221

10

Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey.

Mendelsohn NJ, Harmatz P, Bodamer O, Burton BK, Giugliani R, Jones SA, Lampe C, Malm G, Steiner RD, Parini R; Hunter Outcome Survey Investigators. Mendelsohn NJ, et al. Genet Med. 2010 Dec;12(12):816-22. doi: 10.1097/GIM.0b013e3181f6e74d. Genet Med. 2010. PMID: 21045710 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

146 results

Search Page